Clinical Report: Investigating Associations Between Medications and Suicide Risk
Overview
This retrospective analysis identifies significant associations between various medications and suicide-related adverse events (SAEs) using the FAERS database. Central nervous system medications were most frequently linked to SAEs, with notable differences observed across age groups.
Background
Suicide remains a critical public health concern, with complex interactions among biological, psychological, and social factors contributing to its risk. Despite existing studies on suicide risk factors, the relationship between medications and suicide has not been systematically analyzed, highlighting a gap in clinical awareness and monitoring. Understanding these associations is essential for improving patient safety and informing clinical practices.
Data Highlights
Drug Class
Age Group
Reported Cases
ROR
CNS Medications
<18 years
Montelukast, Isotretinoin, Sertraline
Higher in <18
CNS Medications
≥65 years
Hydrocodone/Acetaminophen
Significantly higher ROR
All Age Groups
All
Quetiapine, Paracetamol
Positive signals
Key Findings
247,657 reports of SAEs involving 193 drugs were analyzed.
Central nervous system medications were most closely associated with SAEs.
SAEs were more likely to occur during the initial stages of medication use.
Montelukast, isotretinoin, and sertraline were the top reported drugs in individuals under 18.
Hydrocodone/acetaminophen showed a significantly higher ROR in individuals aged 65 and older.
Quetiapine and paracetamol exhibited positive signals across all age groups.
Clinical Implications
Clinicians should be vigilant in monitoring patients, particularly adolescents and older adults, who are prescribed medications associated with increased suicide risk. Enhanced awareness of the timing of SAEs can inform safer prescribing practices and patient counseling.
Conclusion
The findings underscore the need for targeted drug safety monitoring and further research to elucidate the mechanisms behind medication-related suicide risks. This knowledge is vital for improving clinical guidelines and patient outcomes.
